Helicobacter pylori infection is a major risk factor for chronic gastritis, digestive ulcers, gastric adenocarcinoma and lymphoma. Due to the decreasing efficacy of anti-H. pylori antibiotic therapy in clinical practice, there is renewed interest in the development of anti-H. pylori vaccines. Bacillus subtilis is non-pathogenic and can produce endospores, which can survive under extreme conditions. These features make the B. subtilis spore an ideal vehicle for delivery of heterologous antigens to extreme environments such as the gastrointestinal tract. In this study, we displayed H. pylori urease B protein on the B. subtilis spore coat using the spore coat protein CotC as a fusion partner. Western blot analyses were used to verify urease B surface expression on spores. Recombinant spores displaying the urease B antigen were used for oral immunization and were shown to generate humoral response in mice. Urease B-specific secretory IgA in faeces and IgG in serum reached significant levels 2 weeks after oral dosing. In addition, oral immunization of recombinant urease B spores induced a significant reduction (84 %) in the stomach bacterial load (0.25±0.13¾10 6 c.f.u.) compared to that in the non-recombinant spores treated group (1.56±0.3¾10 6 c.f.u.; P,0.01). This report shows that urease B expressed on B. subtilis spores was immunogenic, and oral administration of urease B spores can provide protection against H. pylori infection.
INTRODUCTIONHelicobacter pylori is a Gram-negative bacterium that colonizes the stomach in approximately half the world's population. Infection may progress to pathological states, such as peptic ulcer disease and gastric adenocarcinoma, resulting in significant morbidity and mortality worldwide (de Martel et al., 2012;Nakamura et al., 2012;Toller et al., 2011; Uemura et al., 2001; You et al., 2012). Current regimens for treatment of H. pylori infection consist of a proton pump inhibitor (PPI) and antibiotics including amoxicillin, clarithromycin and metronidazole. Despite an eradication rate greater than 80 %, there are some limitations to the PPI-based triple therapy, such as poor patient compliance, emerging antibiotic resistance, frequent reinfection and high cost (Lee et al., 2013;Su et al., 2013). Vaccination would therefore be a suitable alternative or complement to antibiotic treatment to eradicate the bacterium and prevent reinfection (Czinn & Blanchard, 2011).Identification of antigens that can induce effective immune responses is a crucial step in vaccine development. Many protein molecules expressed by H. pylori have been shown to possess immunogenicity, including urease, cytotoxinassociated antigen, neutrophil-activating protein A, H. pylori adhesin A, vacuolating toxin A, catalase and outermembrane protein (Czinn & Blanchard, 2011;Liu et al., 2011).Among these antigens the B subunit of the urease protein (urease B), a 61 kDa protein encoded by a 1.7 kbp gene, is the most promising one. H. pylori produces a large amount of urease, which is essential for the survival and path...